Citations

Clear

196 citation(s) found for "Schultz, M".

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse, John B. , Kahn, Steven E. , Aroda, Vanita R. , Auchus, Richard J. , Busch, Robert S. , Christofides, Elena A. , DeFronzo, Ralph A. , Eilerman, Bradley , Findling, James W. , Handelsman, Yehuda , Miller, Harold J., Ownby, Jonathan G., Parker, John C. , Philis‐Tsimikas, Athena , Rosenstock, Julio , Shanik, Michael H., Sloan, Lance L., Tudor, Iulia Cristina , Schlafly, Tina K. , Einhorn, Daniel , Investigators*, CATALYST, Kruszon, Lauren, Fruiterman, Abbey, Handelsman, Yehuda, Heidarpour, Narges, Ownby, Jonathan G., Stephens, Nashia, Aroda, Vanita R., Gyurko, Rita, Rao, Pratibha, Paulus, Kelly, Kipnes, Mark, Ryan, Terri, Shanik, Michael H., Iannuzzi, Lisa, Umpierrez, Guillermo, Centeno, Gloria, Eskeland, Andrew, Swerdloff, Ronald S., Ruiz, Elizabeth, Park, Jean, Hurtado, Maria, Ghazi, Adline , Hamm, M., Ducote, Rosina, Blonde, Lawrence , Williams, Shannon, Wyne, Kathleen , Aldrich, Lindsey, Ahmann, Andrew , Branigan, Deborah , Nakhle, Samer, Sandry, Sasha, Rosal, Rosario, Hardy, Cashmere, Sloan, Lance , Sloan, Kátia Portero , Lerman, Sam, Simmons, Mary, Auchus, Richard J., Varela, Tamara Blanco, Gassaway, Franziska, DeFronzo, Ralph A., Puckett, Curtiss, Atkinson, Karen, Zimmerman, Michael, Jacobsen, Colleen, Wenker, Matthew, Schultz, Austin, Lender, Dan, Camacho, Allison, Leibowitz, Mark D., Sánchez, Rosario, Delgado, John , Jaasko, Kari, Hsia, Stanley H. , Rodríguez, Cecilia, Guzman, David , Garibay, Lourdes, Chang, Margaret, Nixon, Tatyana, Christofides, Elena A , DeFronzo, Ralph A , Eilerman, Bradley , Fonseca, Vivian , Handelsman, Yehuda , Rosenstock, Julio , Umpierrez, Guillermo E. , Schlafly, Tina K , Philis-Tsimikas, Athena , Kahn, Steven , Buse, John B , Bailey, Timothy S. , Bancos, Irina , Fonseca, Vivian , Hamidi, Oksana , Pratley, Richard E. , Sloan, Lance L., Investigators*, CATALYST, Handelsman, Yehuda, Ownby, Jonathan G., Aroda, Vanita R., Shanik, Michael H., Umpierrez, Guillermo, Centeno, Gloria, Ruiz, Elizabeth, Aldrich, Lindsey, Botte, Jennifer, Hardy, Cashmere, Martin, Maria Jesus , Lovre, Dragana , Simmons, Mary, Auchus, Richard J., Pop‐Busui, Rodica , DeFronzo, Ralph A., Zimmerman, Michael, Wenker, Matthew, Schultz, Austin, Chang, Margaret, Nixon, Tatyana

Mayo Clinic

Diabetes Care | May 7, 2025 | Volume: 48 | Issue: 12 | Pages: 2012-2020

10.2337/dc24-2841 | PMID 40249765 Get It

OBJECTIVE Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control. RESEARCH DESIGN AND METHODS Individuals with type 2 diabetes and HbA1c 7.5%–11.5% (58–102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure–lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed. RESULTS Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure–lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium–glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure–lowering medications (1.390); older age (1.316); BMI <30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P < 0.03). CONCLUSIONS Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.
Prognostic Significance of Germline DICER1 Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor
Nelson, Alexander T. , Watson, David , Chen, Kenneth , Olson, Damon R. , Stall, Jennifer N., Devins, Kyle M. , Young, Robert H. , Kamihara, Junne , Mallinger, Paige, Kim, Jung , Hatton, Jessica N. , Schneider, Dominik T. , Harris, Anne K. , Dehner, Louis P. , Schultz, Kris Ann P. , Watson, Dave , Chen, Kenneth S , Mallinger, Paige H R , Messinger, Yoav H , Frazier, A Lindsay , Stewart, Douglas R , Harris, Anne K , Dehner, Louis P , Hill, Dana Ashley , Schultz, Kris Ann P , Olson, Damon R , Schneider, Dominik T , Devins, Kyle M , Messinger, Yoav H.

Mayo Clinic

JCO Precision Oncology | April 23, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00902 | PMID 40267387 Get It

PURPOSE Sertoli-Leydig cell tumors (SLCTs) are rare sex cord-stromal tumors, representing <0.5% of all ovarian tumors. We analyze the role of germline DICER1 status in outcomes of ovarian SLCT. METHODS Patients with SLCT were enrolled in the International Pleuropulmonary Blastoma/ DICER1 Registry and/or the International Ovarian and Testicular Stromal Tumor Registry. Medical records were systematically abstracted, and those with known germline DICER1 status were selected for analysis. RESULTS Of 162 patients with SLCT, 60% had a germline DICER1 pathogenic or likely pathogenic (P/LP) variant. The adjusted 3-year recurrence-free survival (RFS) was 87.2% (95% CI, 79.4 to 95.8) for patients with a germline DICER1 P/LP variant compared with 78.1% (95% CI, 66.4 to 91.9) for those without a germline DICER1 P/LP variant ( P = .043). The adjusted 3-year and 5-year overall survival (OS) was 93.9% (95% CI, 87.3 to 100.0) for those with a germline DICER1 P/LP variant compared with the 3-year OS of 91.3% (95% CI, 83.4 to 100.0) and the 5-year OS of 78.2% (95% CI, 63.8 to 95.9) for those without a germline DICER1 P/LP variant ( P = .021). Among patients with a germline DICER1 P/LP variant, the risk of a subsequent, nonrecurrent event was 36.2% (95% CI, 21.4 to 48.1) within 10 years. Previous/concurrent and subsequent neoplasms were rare among those without a germline DICER1 P/LP variant. CONCLUSION This cohort study of patients with SLCT demonstrated that those with germline DICER1 P/LP variants had superior RFS and OS even when adjusting for other prognostic factors. Beyond prognostic implications of a germline DICER1 P/LP variant, germline testing helps identify patients at risk of subsequent neoplasms, including metachronous SLCT.
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries
Harris, Anne K. , Nelson, Alexander T. , Watson, Dave , Mallinger, Paige, Stering, Allen I., Snyder, Stacy L., Levy, Carolyn Fein , Kamihara, Junne , Herzog, Cynthia E. , Lagmay, Joanne , Foresto, Steve, Young, Robert H. , Dehner, Louis P. , Tadavarthy, Anil K., Stall, Jennifer N., Billmire, Deborah F., Schneider, Dominik T. , Schultz, Kris Ann P. , Kamihara, Junne , Chen, Kenneth S , Devins, Kyle M , Schneider, Dominik T , Schultz, Kris Ann P , Levy, Carolyn Fein , Harris, Anne K , Messinger, Yoav H. , Frazier, A Lindsay , Chen, Kenneth , Devins, Kyle M. , Hill, Dana Ashley

Mayo Clinic

Cancer | April 23, 2025 | Volume: 131 | Issue: 9 | Pages: No page available

10.1002/cncr.35862 | PMID 40267023 Get It

AbstractBackgroundOvarian juvenile granulosa cell tumors (juvGCT) are rare sex cord‐stromal tumors that occur primarily in children and adolescents. This study summarizes the clinical presentation and outcomes of patients with juvGCT.MethodsPatients were enrolled in the International Ovarian and Testicular Stromal Tumor and/or International Pleuropulmonary Blastoma/DICER1 Registries. Available medical records were abstracted, and pathology was centrally reviewed. Surgical staging was classified using the 2014 International Federation of Gynecology and Obstetrics (FIGO) criteria.ResultsIn total, 70 patients with juvGCT enrolled and were diagnosed between 2001 and 2024; most patients (81%, 57 of 70) presented with FIGO stage I disease. Adjuvant chemotherapy was given in 30% (21 of 70); all regimens were platinum‐based. Three‐year event‐free survival among patients with stage IA tumors was 80.2% (95% confidence interval [CI], 62.4%–100.0%), IC1 was 87.4 (95% CI, 72.4%–100.0%), IC2‐IC3 was 63.6% (95% CI, 40.7%–99.5%), and II‐IV was 48% (95% CI, 24.6%–93.8%). Of the patients with recurrent juvGCT with known mitotic index (MI), all had MI greater than 19 mitoses per 10 high power fields (HPF) at diagnosis.ConclusionOutcomes were worse for patients with FIGO stage ≥IC2 disease and for tumors with >19 mitoses per 10 HPF. Given the prognostic significance of MI, the authors strongly recommend the assessment of MI for all juvGCTs. More information about tumor biology is critical to identify which patients may benefit from adjuvant chemotherapy and to facilitate the development of novel therapies.
Biochemical Assay to Aid in the Diagnosis of SORD Deficiency (P7-2.012)
Laxen, William , Gavrilov, Dimitar , Tortorelli, Silvia , Matern, Dietrich , Schultz, Matthew , Oglesbee, Devin , Hall, Patricia , White, Amy

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211976 Get It

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease
Coughlan, Gillian , Klinger, Hannah M , Boyle, Rory , Binette, Alexa Pichet , Christenson, Luke R., Chadwick, Trevor, Healy, Brian C. , Jonaitis, Erin M. , Jack, Clifford R. , Johnson, Keith A. , Langhough, Rebecca E., Properzi, Michael J , Seto, Mabel , Johnson, Sterling C., Shirzadi, Zahra , Yau, Wai‐Ying Wendy , Initiative, Alzheimer’s Disease Neuroimaging, Hurko, Orest, Black, Sanra E, Doody, Rachelle S., Doraiswamy, Murali, Gamst, Anthony, Scharre, Doug, Sperling, Reisa, Weiner, Michael W. , Green, Robert C, Christenson, Luke, Jack, Clifford R , Pichet Binette, Alexa , Betthauser, Tobey J. , Hansson, Oskar , Harrison, Theresa M. , Jacobs, Heidi I.L. , Hanseeuw, Bernard , Rentz, Dorene M. , Schultz, Aaron P. , Smith, Ruben , Johnson, Sterling C. , Mielke, Michelle M. , Manson, JoAnn E. , Sperling, Reisa Anne , Vemuri, Prashanthi , Buckley, Rachel F. , Initiative, Alzheimer’s Disease Neuroimaging, Black, Sanra E, Kaye, Jeffrey , Obisesan, Thomas O. , Rusinek, Henry

Mayo Clinic

JAMA Neurology | March 3, 2025 | Volume: 82 | Issue: 4 | Pages: 364

10.1001/jamaneurol.2025.0013 | PMID 40029638 Get It

Importance Alzheimer disease (AD) predominates in females at almost twice the rate relative to males. Mounting evidence in adults without AD indicates that females exhibit higher tau deposition than age-matched males, particularly in the setting of elevated β-amyloid (Aβ), but the evidence for sex differences in tau accumulation rates is inconclusive. Objective To examine whether female sex is associated with faster tau accumulation in the setting of high Aβ (as measured with positron emission tomography [PET]) and the moderating influence of sex on the association between APOE ε4 carrier status and tau accumulation. Data Sources This meta-analysis used data from 6 longitudinal aging and AD studies, including the Alzheimer’s Disease Neuroimaging Initiative, Berkeley Aging Cohort Study, BioFINDER 1, Harvard Aging Brain Study, Mayo Clinic Study of Aging, and Wisconsin Registry for Alzheimer Prevention. Longitudinal data were collected between November 2004 and May 2022. Study Selection Included studies required available longitudinal [ 18 F]flortaucipir or [ 18 F]-MK-6240 tau-PET scans, as well as baseline [ 11 C] Pittsburgh Compound B, [ 18 F]flutemetamol or [ 18 F]florbetapir Aβ-PET scans. Recruitment criteria varied across studies. Analyses began on August 7, 2023, and were completed on February 5, 2024. Data Extraction and Synthesis In each study, primary analyses extracted estimates for the sex (female or male) and the sex by baseline Aβ-PET status (high or low) association with longitudinal tau-PET using a series of mixed-effects models. Secondary mixed-effects models extracted the interaction estimate for the association of sex by APOE ε4 carrier status with longitudinal tau-PET. Study-specific estimates for each mixed-effects model were then pooled in a meta-analysis, and the global fixed effect (β) and total heterogeneity ( I 2 ) across studies were estimated. This study is reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Main Outcomes and Measures Seven tau-PET outcomes that showed cross-sectional sex differences were examined across temporal, parietal, and occipital lobes. Results Among 6 studies assessed, there were 1376 participants (761 [55%] female; mean [range] age at first tau scan, 71.9 [46-93] years; 401 participants [29%] with high baseline Aβ; 412 APOE ε4 carriers [30%]). Among individuals with high baseline Aβ, female sex was associated with faster tau accumulation localized to inferior temporal (β = −0.14; 95% CI, −0.22 to −0.06; P = .009) temporal fusiform (β = −0.13; 95% CI, −0.23 to −0.04; P = .02), and lateral occipital regions (β = −0.15; 95% CI, −0.24 to −0.06; P = .009) compared with male sex. Among APOE ε4 carriers, female sex was associated with faster inferior-temporal tau accumulation (β = −0.10; 95% CI, −0.16 to −0.03; P = .01). Conclusions and Relevance These findings suggest that sex differences in the pathological progression of AD call for sex-specific timing considerations when administrating anti-Aβ and anti-tau treatments.
Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition
Fiorica, Peter N. , Golmard, Lisa , Kim, Jung , Bao, Riyue , Lin, Frank Y. , Roy, Angshumoy , Pribnow, Allison , Perrino, Melissa R. , Masliah‐Planchon, Julien , Michalak-Provost, Sophie , Wong, Jennifer , Filser, Mathilde , Bourdeaut, Franck , Brahimi, Afane, Ingster, Olivier, Jackson, Sarah A. , Sasaki, Mark M. , Fowler, Trent, Ng, Anita , Corbett, Ryan J. , Kaufman, Rebecca , Haley, Jeremy S. , Carey, David J. , Huang, Kuan‐lin , Diskin, Sharon J. , Al‐Kateb, Hussam , Schultz, Kris Ann P. , Onel, Kenan , Stoppa-Lyonnet, Dominique , Bourdeaut, Franck , Brahimi, Afane , Ingster, Olivier , Saulnier Sholler, Giselle , Jackson, Sarah A , Sasaki, Mark M , Fowler, Trent , Ng, Anita , Corbett, Ryan J , Kaufman, Rebecca S , Haley, Jeremy S , Carey, David J , Huang, Kuan-Lin , Diskin, Sharon J , Rokita, Jo Lynne , Al-Kateb, Hussam , McGee, Rose B , Schiffman, Joshua D , Chen, Kenneth S , Stewart, Douglas R , Parsons, D Williams , Plon, Sharon E. , Schultz, Kris Ann P , Onel, Kenan , Perrino, Melissa R , Lin, Frank Y , Stoppa‐Lyonnet, Dominique , Rokita, Jo Lynne , Chen, Kenneth , Parsons, D. Williams

Mayo Clinic

Clinical Cancer Research | February 24, 2025 | Volume: 31 | Issue: 8 | Pages: 1491-1503

10.1158/1078-0432.ccr-24-2785 | PMID 39992227 Get It

Abstract Purpose: DROSHA, DGCR8, and DICER1 regulate miRNA biogenesis and are commonly mutated in cancer. Although DGCR8 and DICER1 germline pathogenic variants (GPV) cause autosomal dominant tumor predisposition, no association between DROSHA GPVs and clinical phenotypes has been reported. Experimental Design: After obtaining informed consent, sequencing was performed on germline and tumor samples from all patients. The occurrence of germline DROSHA GPVs was investigated in large pediatric and adult cancer datasets. The population prevalence of DROSHA GPVs was investigated in the UK Biobank and Geisinger DiscovEHR cohorts. Results: We describe nine children from eight families with heterozygous DROSHA GPVs and a diagnosis of pineoblastoma (n = 8) or Wilms tumor (n = 1). A somatic second hit in DROSHA was detected in all eight tumors analyzed. All pineoblastoma tumors analyzed were classified as miRNA processing–altered 1 subtype. We estimate the population prevalence of germline DROSHA loss-of-function variants to be 1:3,875 to 1:4,843 but find no evidence for increased adult cancer risk. Conclusions: This is the first report of DROSHA-related tumor predisposition. As pineoblastoma and Wilms tumor are also associated with DICER1 GPVs, our results suggest that the tissues of origin for these tumors are uniquely tolerant of general miRNA loss. The miRNA processing–altered 1 pineoblastoma subtype is associated with older age of diagnosis and better outcomes than other subtypes, suggesting DROSHA GPV status may have important clinical and prognostic significance. We suggest that genetic testing for DROSHA GPVs be considered for patients with pineoblastoma, Wilms tumor, or other DICER1-/DGCR8-related conditions and propose surveillance recommendations through research studies for individuals with DROSHA GPVs.
Rethinking the residual approach for estimating cognitive resilience and resistance to AD pathology
Cuppels, Madison, Klinger, Hannah M , Langford, Oliver , Chhatwal, Jasmeer P. , Price, Julie C. , Properzi, Michael J , Amariglio, Rebecca E. , Johnson, Keith A. , Mukherjee, Shubhabrata , Resnick, Susan M. , Tunali, Ilke, Landau, Susan , Lockhart, Samuel N. , Birkenbihl, Colin J. , Boyle, Rory , Coughlan, Gillian , Schultz, Aaron P. , Rentz, Dorene M. , Gottesman, Rebecca F. , Maruff, Paul , Lim, Yen Ying , Masters, Colin L. , Beiser, Alexa , Burnham, Samantha C. , Cohen, Ann D. , Johnson, Sterling C. , Betthauser, Tobey J. , Seshadri, Sudha , Lockhart, Samuel N. , O’Bryant, Sid E. , Vemuri, Prashanthi , Sperling, Reisa Anne , Hohman, Timothy J. , Donohue, Michael , Buckley, Rachel F.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.094824 Get It

AbstractBackgroundThe residual approach has found wide application in researching cognitive resilience, a phenomenon conceptually understood as cognitive performance being better‐than‐typical for an individual, despite apparent AD pathology. The standard residual approach extracts information about an individual’s resilience from the residuals of a linear model predicting cognition. This approach is subject to several limiting assumptions. Here, we explore the implications of these assumptions and propose an alternative predictive modeling approach which circumvents them.MethodsOur alternative approach relies on training a machine learning model on a sample of participants who follow a “typical” clinical progression (Fig. 1A). Residuals are then extracted for a heterogeneous dataset that potentially includes resilient participants by comparing observed cognitive outcomes to those predicted by the “typical” model (Fig. 1B). Additionally, our estimate can be refined by effectively estimating and removing model error from the extracted residual by leveraging a second predictive model (Fig. 1C). Using simulated data, we explore the assumptions made by the standard approach and the consequences of their violation. We then contrast this against our approach.ResultsOur simulations demonstrated that the standard residual approach only extracted accurate resilience estimates if the predictors used in the model explained cognition sufficiently well, while being unrelated to resilience itself. That is, as the predictors explain more of the resilience, the residuals became increasingly determined by model error (Fig. 2). We found that residuals achieved with our approach are more precise and provide individualized estimates that are unaffected by the aforementioned trade‐off (Fig. 3).ConclusionsOur approach holds several advantages over the standard approach: The definition of resilience can be freely adjusted and enforced via different definitions of “typical”, it allows for incorporating complex, non‐linear models without removing relevant information from the residual, the error component of the residual can be estimated through cross‐validation, and all predictors that potentially explain cognition can be included into the model without losing resilience information from the residual. Our approach can be used to measure any phenomenon that can be operationalized as a deviation from a typical outcome and, thus, is also applicable for researching resistance to pathology.
CSF proteomics related to the neurovascular unit are associated with white matter hyperintensity volumes and cerebral microhemorrhages in autosomal dominant Alzheimer disease
Shen, Yuanyuan , Chen, Charles D., Strain, Jeremy F. , Shirzadi, Zahra , Chen, Gengsheng , Massoumzadeh, Parinaz , Lu, Ruijin , Chhatwal, Jasmeer P. , Morris, John C., Perrin, Richard J. , Network, Dominantly Inherited Alzheimer, Joseph‐Mathurin, Nelly , Friedrichsen, Karl A. , McCullough, Austin , Gordon, Brian A. , Llibre‐Guerra, Jorge J. , Hassenstab, Jason , Ibanez, Laura , Schultz, Stephanie A. , Morris, John C. , An, Hongyu , Xiong, Chengjie , Klein, Robyn S. , Jack, Clifford R. , Bateman, Randall J. , McDade, Eric , Benzinger, Tammie L.S. , Cruchaga, Carlos

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.084578 Get It

AbstractBackgroundAutosomal dominant Alzheimer disease (ADAD) is characterized by genetic mutations affecting the beta‐amyloid (Aβ) pathway. However, vascular and immune factors play important roles which are not completely understood. Understanding the function of the neurovascular unit (NVU) comprised of neurons, glial cells, and vasculature, at different disease stages appears ideal to developing and evaluating therapeutics. Omics approaches can inform NVU changes and their disease associations.MethodsCSF proteomic data using the Somalogic® platform was generated from 485 participants in the DIAN study, who also had PiB‐PET and MRI assessing Aβ burden, white matter hyperintensity (WMH), and cerebral microhemorrhage (CMH). From previously published AD studies, we identified 33 NVU‐associated proteins with corresponding Somalogic aptamers (Figure 1). We used Principal Component Analysis (PCA) on participants with complete data (n=262, 166 mutation‐carriers and 96 non‐carriers) to find groups of proteins associated with mutation status and disease stage as measured with estimated year to symptom onset (EYO), PiB‐PET, and clinical status. Linear‐mixed effect models and two‐part zero‐inflated negative binomial mixed models further evaluated the link between significant principal components (PCs) and WMH and CMH, respectively. Models accounted for age, APOE‐e4 status, sex, and education.ResultsThe first ten PCs explained >60% of the variance in NVU‐related protein levels (Figure 2A) with only PC5 (4.8%) associated with mutation*EYO, suggesting relationship with ADAD‐specific disease progression (***p<0.0001, Figure 2B). While asymptomatic PiB‐negative individuals were not significantly different from non‐carriers, asymptomatic PiB‐positive individuals had higher PC5 scores than non‐carriers and symptomatic individuals scored still higher (**p<0.005, ***p<0.0001, Figure 2C). The main proteins composing PC5 were: neurofilament light‐chain, angiopoietin‐2, SMOC1, LRP1, E‐selectin, and sTREM2, suggesting strong association with proinflammatory glial response from neuronal injury (Figure 2D). PC5 was also associated with WMH volumes (*p<0.05, Figure 3A) and with CMH count in participants with CMH (**p<0.005, Figure 3B).ConclusionsThis PCA approach indicates that some groups of NVU‐associated proteins are related with mutation status and disease stage, and that they are differentially associated with features of ADAD such as white matter integrity as measured by WMH volume. Weighted Correlation Network Analysis will be of interest to further understand these associations.Funding: K01AG080123, RF1‐AG044546, UF1AG032438
CSF proteomics related to the neurovascular unit are associated with white matter hyperintensity volumes and cerebral microhemorrhages in autosomal dominant Alzheimer disease
Shen, Yuanyuan , Chen, Charles D., Strain, Jeremy F. , Shirzadi, Zahra , Chen, Gengsheng , Massoumzadeh, Parinaz , Lu, Ruijin , Chhatwal, Jasmeer P. , Perrin, Richard J. , Joseph‐Mathurin, Nelly , Friedrichsen, Karl A. , McCullough, Austin , Gordon, Brian A. , Llibre‐Guerra, Jorge J. , Hassenstab, Jason , Ibanez, Laura , Schultz, Stephanie A. , Morris, John C. , An, Hongyu , Xiong, Chengjie , Klein, Robyn S. , Jack, Clifford R. , Bateman, Randall J. , McDade, Eric , Benzinger, Tammie L.S. , Cruchaga, Carlos

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093619 Get It

AbstractBackgroundAutosomal dominant Alzheimer disease (ADAD) is characterized by genetic mutations affecting the beta‐amyloid (Aß) pathway. However, vascular and immune factors play important roles which are not completely understood. Understanding the function of the neurovascular unit (NVU) comprised of neurons, glial cells, and vasculature, at different disease stages appears ideal to developing and evaluating therapeutics. Omics approaches can inform NVU changes and their disease associations.MethodsCSF proteomic data using the Somalogic® platform was generated from 485 participants in the DIAN study, who also had PiB‐PET and MRI assessing Aß burden, white matter hyperintensity (WMH), and cerebral microhemorrhage (CMH). From previously published AD studies, we identified 33 NVU‐associated proteins with corresponding Somalogic aptamers (Figure 1). We used Principal Component Analysis (PCA) on participants with complete data (n = 262, 166 mutation‐carriers and 96 non‐carriers) to find groups of proteins associated with mutation status and disease stage as measured with estimated year to symptom onset (EYO), PiB‐PET, and clinical status. Linear‐mixed effect models and two‐part zero‐inflated negative binomial mixed models further evaluated the link between significant principal components (PCs) and WMH and CMH, respectively. Models accounted for age, APOE‐e4 status, sex, and education.ResultsThe first ten PCs explained >60% of the variance in NVU‐related protein levels (Figure 2A) with only PC5 (4.8%) associated with mutation*EYO, suggesting relationship with ADAD‐specific disease progression (***p<0.0001, Figure 2B). While asymptomatic PiB‐negative individuals were not significantly different from non‐carriers, asymptomatic PiB‐positive individuals had higher PC5 scores than non‐carriers and symptomatic individuals scored still higher (**p<0.005, ***p<0.0001, Figure 2C). The main proteins composing PC5 were: neurofilament light‐chain, angiopoietin‐2, SMOC1, LRP1, E‐selectin, and sTREM2, suggesting strong association with proinflammatory glial response from neuronal injury (Figure 2D). PC5 was also associated with WMH volumes (*p<0.05, Figure 3A) and with CMH count in participants with CMH (**p<0.005, Figure 3B).ConclusionsThis PCA approach indicates that some groups of NVU‐associated proteins are related with mutation status and disease stage, and that they are differentially associated with features of ADAD such as white matter integrity as measured by WMH volume. Weighted Correlation Network Analysis will be of interest to further understand these associations. Funding: K01AG080123, RF1‐AG044546, UF1AG032438